4
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lifetime cardiovascular management of patients with previous Kawasaki disease

      review-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Kawasaki disease (KD) is an inflammatory disorder of young children, associated with vasculitis of the coronary arteries with subsequent aneurysm formation in up to one-third of untreated patients. Those who develop aneurysms are at life-long risk of coronary thrombosis or the development of stenotic lesions, which may lead to myocardial ischaemia, infarction or death. The incidence of KD is increasing worldwide, and in more economically developed countries, KD is now the most common cause of acquired heart disease in children. However, many clinicians in the UK are unaware of the disorder and its long-term cardiac complications, potentially leading to late diagnosis, delayed treatment and poorer outcomes. Increasing numbers of patients who suffered KD in childhood are transitioning to the care of adult services where there is significantly less awareness and experience of the condition than in paediatric services. The aim of this document is to provide guidance on the long-term management of patients who have vascular complications of KD and guidance on the emergency management of acute coronary complications. Guidance on the management of acute KD is published elsewhere.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association

          Kawasaki disease is an acute vasculitis of childhood that leads to coronary artery aneurysms in ≈25% of untreated cases. It has been reported worldwide and is the leading cause of acquired heart disease in children in developed countries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

            Treatment of acute Kawasaki syndrome with a four-day course of intravenous gamma globulin, together with aspirin, has been demonstrated to be safe and effective in preventing coronary-artery lesions and reducing systemic inflammation. We hypothesized that therapy with a single, very high dose of gamma globulin would be at least as effective as the standard regimen. We conducted a multicenter, randomized, controlled trial involving 549 children with acute Kawasaki syndrome. The children were assigned to receive gamma globulin either as a single infusion of 2 g per kilogram of body weight over 10 hours or as daily infusions of 400 mg per kilogram for four consecutive days. Both treatment groups received aspirin (100 mg per kilogram per day through the 14th day of illness, then 3 to 5 mg per kilogram per day). The relative prevalence of coronary abnormalities, adjusted for age and sex, among patients treated with the four-day regimen, as compared with those treated with the single-infusion regimen, was 1.94 (95 percent confidence limits, 1.01 and 3.71) two weeks after enrollment and 1.84 (95 percent confidence limits, 0.89 and 3.82) seven weeks after enrollment. Children treated with the single-infusion regimen had lower mean temperatures while hospitalized (day 2, P less than 0.001; day 3, P = 0.004), as well as a shorter mean duration of fever (P = 0.028). Furthermore, in the single-infusion group the laboratory indexes of acute inflammation moved more rapidly toward normal, including the adjusted serum albumin level (P = 0.004), alpha 1-antitrypsin level (P = 0.007), and C-reactive protein level (P = 0.017). Lower IgG levels on day 4 were associated with a higher prevalence of coronary lesions (P = 0.005) and with a greater degree of systemic inflammation. The two groups had a similar incidence of adverse effects (including new or worsening congestive heart failure in nine children), which occurred in 2.7 percent of the children overall. All the adverse effects were transient. In children with acute Kawasaki disease, a single large dose of intravenous gamma globulin is more effective than the conventional regimen of four smaller daily doses and is equally safe.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Epidemiology of Kawasaki Disease in Asia, Europe, and the United States

              Kawasaki disease (KD) is a systemic vasculitis that mainly affects children younger than 5 years. Although Dr. Tomisaku Kawasaki first reported KD over 40 years ago, the cause of the disease remains unknown. Currently, KD has been diagnosed in more than 60 countries, including those in Asia, the Middle East, Latin America, and Africa, as well as in North America and Europe. The purpose of this review is to describe the epidemiologic features of KD—particularly its incidence, seasonality, and the occurrence of coronary artery abnormalities—primarily in Japan and the United States, but also in Europe and other Asian countries.
                Bookmark

                Author and article information

                Journal
                Heart
                Heart
                heartjnl
                heart
                Heart
                BMJ Publishing Group (BMA House, Tavistock Square, London, WC1H 9JR )
                1355-6037
                1468-201X
                March 2020
                16 December 2019
                : 106
                : 6
                : 411-420
                Affiliations
                [1 ] departmentInfection, Inflammation, and Rheumatology , UCL Institute of Child Health , London, UK
                [2 ] departmentPediatrics , University of California , San Diego, California, USA
                [3 ] departmentPediatrics , Rady Children’s Hospital San Diego , San Diego, California, USA
                [4 ] departmentNational Clinical Director Children, Young People and Transition to Adulthood, Medical Directorate , NHS England , London, UK
                [5 ] departmentNHS Improvement , NHS England , London, UK
                [6 ] departmentCardiology , Sharp Memorial Hospital and San Diego Cardiac Center , San Diego, California, USA
                [7 ] departmentNational Clinical Director for Heart Disease , NHS England , London, UK
                [8 ] departmentCardiology , Bristol Heart Institute , Bristol, UK
                [9 ] departmentPaediatrics , Imperial College London , London, UK
                [10 ] departmentImperial College London , International Centre for Circulatory Health , London, UK
                [11 ] departmentCardiology , Kings College Hospital , London, UK
                [12 ] Societi, The UK Foundation for Kawasaki Disease , Newark, UK
                [13 ] departmentDepartment of Congenital Heart Disease , Evelina London Children’s Hospital, Guy’s and St. Thomas’ NHS Foundation Trust , London, UK
                [14 ] departmentDepartment of Congenital Heart Disease , Bristol Royal Hospital for Children , Bristol, UK
                [15 ] departmentUniversity of Bristol , Bristol Heart Institute , Bristol, UK
                Author notes
                [Correspondence to ] Professor Robert M R Tulloh, Department of Congenital Heart Disease, Bristol Royal Hospital for Children, Bristol BS2 8BJ, UK; robert.tulloh@ 123456bristol.ac.uk
                Author information
                http://orcid.org/0000-0002-3180-6993
                Article
                heartjnl-2019-315925
                10.1136/heartjnl-2019-315925
                7057818
                31843876
                3107d486-c33b-436b-bd4e-964ae996caeb
                © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

                This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:  http://creativecommons.org/licenses/by-nc/4.0/.

                History
                : 04 September 2019
                : 05 November 2019
                : 07 November 2019
                Categories
                Expert Consensus Statement
                1506
                1490
                Review
                Custom metadata
                unlocked
                true

                Cardiovascular Medicine
                kawasaki disease,lifetime cardiovascular management,coronary artery aneurysm,late sequelae,acute coronary syndrome,cardiovascular risk,person specific protocol,transitional care

                Comments

                Comment on this article